Iressa 250 mg Alternative – Gefinix (Gefitinib) 250 mg Tablet | Beacon Pharmaceuticals

Product Overview

Gefinix 250 mg Tablet is listed in the supplied Beacon Pharmaceuticals anti-cancer and hematology price list. The stated active ingredient is Gefitinib. Iressa is a reference brand for the generic ingredient. This is a product-identification comparison, not a claim of verified bioequivalence or interchangeability.

Gefinix vs Iressa – Reference Brand Comparison

Iressa is a recognized reference brand associated with Gefitinib. Gefinix is listed under Beacon Pharmaceuticals. Their excipients, marketing authorizations, formulation details and regulatory evidence may differ. A clinician or pharmacist must confirm whether substitution is appropriate.

Composition and Active Ingredient

Brand: Gefinix. Active ingredient: Gefitinib. Strength: 250 mg. Dosage form: Tablet. Therapeutic class: EGFR inhibitor. Listed manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Packaging details should be confirmed on the manufacturer’s current pack.

Therapeutic Uses and Indications

Gefitinib is used in selected EGFR-mutated lung cancer. These are generic-level clinical contexts and do not independently confirm every indication for this particular branded presentation. Eligibility may depend on biomarkers, previous therapy and country-specific labeling.

Mechanism of Action – How Gefitinib Works

Gefitinib blocks EGFR kinase activity. This mechanism alone does not establish suitability or effectiveness for an individual patient.

Dosage and Administration

The 250 mg shown is the strength of this tablet, not a recommended daily dose. Dose, timing, food instructions and treatment duration must be determined by the treating specialist using the current authorized prescribing information. Do not change dose or substitute brands or strengths without medical approval.

Contraindications

Contraindications depend on Gefitinib, formulation and individual medical conditions. Review the current official prescribing information, particularly hypersensitivity, pregnancy-related and organ-function restrictions.

Warnings and Precautions

Important safety considerations include rash, diarrhea and interstitial lung disease. The prescriber may require laboratory testing, cardiac or organ-function assessment, and ongoing monitoring.

Possible Side Effects

Potential adverse effects and serious reactions include rash, diarrhea and interstitial lung disease. Other reactions can occur. Consult the product leaflet for the full adverse-effect profile and seek medical care for severe symptoms.

Drug Interactions

Drug interactions may affect treatment effectiveness or toxicity. Inform the treating clinician of all prescriptions, over-the-counter products, herbal supplements and other treatments.

Pregnancy, Fertility and Breastfeeding

Some oncology and hematology medicines can cause fetal harm and require specific contraception or breastfeeding restrictions. Follow the medicine-specific official labeling and specialist advice.

Storage and Handling

Store according to the instructions printed on the actual Beacon Pharmaceuticals pack. Protect from inappropriate heat, humidity and light, and keep out of reach of children. Do not assume the storage conditions of another brand apply.

Why Is Gefinix Listed as an Alternative to Iressa?

The comparison helps identify another listed brand containing Gefitinib. It does not establish identical formulation, regulatory approval, bioequivalence or permission to substitute.

Manufacturer Information

Listed brand: Gefinix. Manufacturer: Beacon Pharmaceuticals Ltd., Bangladesh. Reference brand: Iressa. Generic: Gefitinib. Strength: 250 mg. Dosage form: Tablet.

Frequently Asked Questions

What is Gefinix 250 mg? It is a tablet containing Gefitinib 250 mg according to the supplied Beacon price list. What is it used for? Gefitinib is used in selected EGFR-mutated lung cancer, subject to specialist assessment. Can it replace Iressa? Not automatically; a qualified professional must check product-specific equivalence and regulatory requirements. Is a prescription required? Yes, appropriate prescription and specialist supervision are necessary.

Important Medical Disclaimer

This listing is for educational pharmaceutical identification only and is not a substitute for medical advice, official product labeling or regulatory review. Brand, strength and pack details should be confirmed against the current manufacturer information before dispensing.